The titre of anti-LGALS3 antibody was 0.1116 ± 0.0353 (mean ± SD, arbitrary unit) in FT1D patients (acute phase, n = 16), 0.1060 ± 0.0344 in FT1D patients (sub-acute phase, n = 16), 0.1245 ± 0.0310 in T1AD patients, 0.1011 ± 0.0213 in T2D patients, 0.1055 ± 0.0192 in AITD patients and 0.0956 ± 0.0329 in HC. This evidence concerns the gene LGALS3 and type 2 diabetes mellitus.